{"result_id": "318040", "URL": "https://www.trialsitenews.com/a/german-live-accentuated-covid-19-vaccine-superior-to-pfizers-bnt162b2-in-early-animal-model-testing-viral-transmission-reduction-bbfd6aa8", "timestamp": "2023-04-25 17:44:02 CEST+0200", "meta": {"description": "Transparent coverage of clinical research", "lang": "en", "keywords": "", "favicon": "", "canonical": "https://www.trialsitenews.com/a/german-live-accentuated-covid-19-vaccine-superior-to-pfizers-bnt162b2-in-early-animal-model-testing-viral-transmission-reduction-bbfd6aa8", "encoding": "utf-8"}, "image": null, "domain": "www.trialsitenews.com", "title": "German Live-Accentuated COVID-19 Vaccine Superior to Pfizer\u2019s BNT162b2 in Early Animal Model Testing Viral Transmission Reduction", "cleaned_text": "", "opengraph": {"image": "https://imagedelivery.net/WEWiZyGwyq-Q4qn_WluYYg/c8a721d7-dbcd-4b3d-6e6a-98bdbfedbd00/public", "description": "Jakob Trimpert with the Institut f&uuml;r Virologie, Freie Universit&auml;t Berlin and a large team of collaborators from various German academic medical centers report that an early-stage, experimental COVID-19 live-attenuated virus vaccine called sCPD9 beat out both Pfizer-BioNTech&rsquo;s BNT162b2 and the adenovirus-vectored spike protein Ad2-spike in a study of viral transmission reductio in animals (Syrian hamsters).\nUsing both homogenous and heterologous vaccination regimens, this early-stage preclinical investigation was based on readouts from virus titrations to single-cell RNA sequencing.&nbsp;"}, "tags": [], "tweets": [], "movies": [], "links": [], "authors": [], "publish_date": null}